GSK’s Arixtra Acute Coronary Syndrome Indication Gets Priority Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Supplemental indication for the anticoagulant has a Jan. 31 user fee date.
You may also be interested in...
GSK’S Arixtra “Approvable” For Acute Coronary Syndromes
Firm is seeking FDA approval of fondaparinux for treatment of unstable angina or non-ST segment elevation myocardial infarction and ST-segment elevation MI.
GSK’S Arixtra “Approvable” For Acute Coronary Syndromes
Firm is seeking FDA approval of fondaparinux for treatment of unstable angina or non-ST segment elevation myocardial infarction and ST-segment elevation MI.
Bayer Moves Anti-Thrombotic Into Phase III For Two Indications
Bayer is set to begin Phase III trials for its antithrombotic agent BAY 59-7939 for a general venous thromboembolism indication following promising Phase II results, the company announced June 12